CY1110982T1 - Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων - Google Patents
Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστωνInfo
- Publication number
- CY1110982T1 CY1110982T1 CY20101101148T CY101101148T CY1110982T1 CY 1110982 T1 CY1110982 T1 CY 1110982T1 CY 20101101148 T CY20101101148 T CY 20101101148T CY 101101148 T CY101101148 T CY 101101148T CY 1110982 T1 CY1110982 T1 CY 1110982T1
- Authority
- CY
- Cyprus
- Prior art keywords
- nucleic acid
- bone
- compositions
- methods
- acid molecule
- Prior art date
Links
- 210000000988 bone and bone Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
Abstract
Απομονωμένο μόριο νουκλεϊνικού οξέος που επιλέγεται από την ομάδα την αποτελούμενη από: (a) ένα απομονωμένο μόριο νουκλεϊνικού οξέος που περιλαμβάνει τις αλληλουχίες Αρ. Ταυτ. 1, 5, 9, 11, 13 ή 15, ή συμπληρωματικές αλληλουχίες αυτών· (b) ένα απομονωμένο μόριο νουκλεϊνικού οξέος που υβριδίζεται επιλεκτικά με το μόριο του νουκλεϊνικού οξέος του (a) υπό συνθήκες υψηλής αυστηρότητας· και (c) ένα απομονωμένο μόριο νουκλεϊνικού οξέος που κωδικοποιεί μία πρωτεΐνη δεσμεύσεως TGF-β σύμφωνα με το (a)4(b).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11028398P | 1998-11-27 | 1998-11-27 | |
EP06011535A EP1721979B1 (en) | 1998-11-27 | 1999-11-24 | Compositions and methods for increasing bone mineralisation |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110982T1 true CY1110982T1 (el) | 2015-06-11 |
Family
ID=22332193
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101623T CY1106260T1 (el) | 1998-11-27 | 2006-11-09 | Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων |
CY20101101148T CY1110982T1 (el) | 1998-11-27 | 2010-12-10 | Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων |
CY20171100914T CY1119263T1 (el) | 1998-11-27 | 2017-08-30 | Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101623T CY1106260T1 (el) | 1998-11-27 | 2006-11-09 | Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100914T CY1119263T1 (el) | 1998-11-27 | 2017-08-30 | Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων |
Country Status (18)
Country | Link |
---|---|
US (12) | US6395511B1 (el) |
EP (3) | EP2261335B1 (el) |
JP (2) | JP4813660B2 (el) |
CN (2) | CN101469329B (el) |
AT (2) | ATE338120T2 (el) |
BR (1) | BRPI9915679B8 (el) |
CA (1) | CA2352532C (el) |
CY (3) | CY1106260T1 (el) |
DE (2) | DE69933044T3 (el) |
DK (3) | DK1721979T3 (el) |
ES (3) | ES2639020T3 (el) |
HK (2) | HK1044171B (el) |
IL (3) | IL143266A0 (el) |
MX (2) | MX343200B (el) |
NZ (3) | NZ512122A (el) |
PT (3) | PT1133558E (el) |
WO (1) | WO2000032773A1 (el) |
ZA (1) | ZA200104234B (el) |
Families Citing this family (160)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020042926A1 (en) * | 1998-10-28 | 2002-04-11 | Matzuk Martin M. | Ovary-specific genes and proteins |
US20040009535A1 (en) * | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
ATE338120T2 (de) * | 1998-11-27 | 2006-09-15 | Ucb Sa | Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung |
WO2000055193A2 (en) * | 1999-03-12 | 2000-09-21 | Regeneron Pharmaceuticals, Inc. | Human dan/cerberus related protein 6 (dcr6) |
US20030138902A1 (en) * | 1999-08-31 | 2003-07-24 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP1290169A2 (en) * | 2000-06-01 | 2003-03-12 | Amgen, Inc. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
EP1857551A3 (en) * | 2000-06-01 | 2007-11-28 | Amgen Inc. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
EP1366156A2 (en) * | 2000-06-19 | 2003-12-03 | F. Hoffmann-La Roche Ag | Osteolevin gene polymorphisms |
AU2002230390A1 (en) * | 2000-10-05 | 2002-04-29 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Ixodes scapularis tissue factor pathway inhibitor |
CA2468125A1 (en) * | 2001-10-24 | 2003-05-01 | Dgi Biotechnologies, Inc. | Target specific screening and its use for identifying target binders |
US7202102B2 (en) * | 2001-11-27 | 2007-04-10 | Jds Uniphase Corporation | Doped absorption for enhanced responsivity for high speed photodiodes |
EP2277522B1 (en) * | 2002-03-01 | 2012-11-21 | UCB Manufacturing, Inc. | Methods for increasing or decreasing bone density and identifying molecules |
US7799523B2 (en) * | 2002-04-03 | 2010-09-21 | Celltech R & D, Inc. | Association of polymorphisms in the SOST gene region with bone mineral density |
US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
WO2003106657A2 (en) * | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
US7585501B2 (en) * | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
ES2379689T3 (es) * | 2003-03-14 | 2012-04-30 | Ucb Manufacturing, Inc. A Company Incorporated Under The Laws Of The State Of Delaware | Complejo de esclerostina y nogina o cordina, y agentes que modulan la formación de dicho complejo |
US20040197828A1 (en) * | 2003-03-26 | 2004-10-07 | Gaddy Dana P. | Method for diagnosis and treatment of bone turnover |
JP3848288B2 (ja) * | 2003-04-25 | 2006-11-22 | キヤノン株式会社 | 放射線画像撮影装置 |
EP1632249A4 (en) * | 2003-06-05 | 2007-12-26 | Nippon Shinyaku Co Ltd | OSTEOGENESIS PROMOTION AMPLIFIER AND SCREENING METHOD THEREFOR |
US7381409B2 (en) | 2003-06-16 | 2008-06-03 | Celltech R&D, Inc. | Antibodies specific for sclerostin and methods of screening and use therefor |
US8461155B2 (en) * | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
WO2005063983A1 (en) * | 2003-12-29 | 2005-07-14 | Galapagos Genomics N.V. | Modulators of bone homeostasis identified in a high-throughput screen |
US8415302B2 (en) | 2004-01-28 | 2013-04-09 | The Regents Of The University Of California | Surgical applications for BMP binding protein |
US8188219B2 (en) | 2004-01-28 | 2012-05-29 | The Regents Of The University Of California | Bone morphogenic protein binding peptide |
US8193312B2 (en) | 2004-01-28 | 2012-06-05 | The Regents Of The University Of California | Bone morphogenic protein binding peptide |
JP2008540328A (ja) * | 2004-11-29 | 2008-11-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 脱灰骨基質(demineralizedbonematrix)の活性化抽出 |
ITMI20050739A1 (it) * | 2005-04-22 | 2006-10-23 | Effebi Spa | Piastrina di connsessione valvola-attuatore |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
WO2006135734A2 (en) * | 2005-06-10 | 2006-12-21 | The Regents Of The University Of California | Compositions and methods for altering bone density and bone patterning |
US8202546B2 (en) | 2005-08-04 | 2012-06-19 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US7998500B2 (en) | 2005-08-04 | 2011-08-16 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
US7901710B2 (en) | 2005-08-04 | 2011-03-08 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for use under physiologically stressful conditions |
US8263137B2 (en) | 2005-08-04 | 2012-09-11 | Vertical Pharmaceuticals, Inc. | Nutritional supplement for women |
EP3811965A1 (en) * | 2005-11-23 | 2021-04-28 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
EP2094731A2 (en) * | 2006-11-10 | 2009-09-02 | UCB Pharma S.A. | Anti human sclerostin antibodies |
WO2008061013A2 (en) * | 2006-11-10 | 2008-05-22 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
ES2666650T3 (es) | 2006-12-29 | 2018-05-07 | OstéoQC Inc. | Métodos para alterar el crecimiento óseo mediante la administración de antagonista o agonista de sost o wise |
US20080200425A1 (en) * | 2007-02-16 | 2008-08-21 | Kurtz Seymour J | Methods and compositions for regulating bone mineral density |
EP2131860B1 (en) | 2007-03-20 | 2013-12-18 | Eli Lilly & Company | Anti-sclerostin antibodies |
EP2171062A1 (en) * | 2007-06-15 | 2010-04-07 | Genzyme Corporation | Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor |
CA2698103A1 (en) * | 2007-08-31 | 2009-03-05 | Amgen Inc. | Solid-state protein formulation |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
WO2009043049A2 (en) | 2007-09-27 | 2009-04-02 | Amgen Inc. | Pharmaceutical formulations |
TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素(sclerostin)抗體組合物及使用方法 |
ES2962777T3 (es) | 2007-11-15 | 2024-03-21 | Amgen Inc | Formulación acuosa de anticuerpos estabilizada por antioxidantes para la administración parenteral |
EP2628486A3 (en) | 2007-12-14 | 2013-10-30 | Amgen, Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
US8518656B2 (en) | 2008-04-02 | 2013-08-27 | Ramot Tel-Aviv University Ltd. | Procollagen C-proteinase enhancer (PCPE) biomarker for bone formation |
WO2009122367A2 (en) * | 2008-04-02 | 2009-10-08 | Tel Hashomer Medical Research Infrastructure And Services Ltd | Procollagen c-proteinase enhancer (pcpe) biomarker for bone formation |
EP2320896A4 (en) * | 2008-07-03 | 2012-08-29 | Osteogenex Inc | VINPOCETINE AND EBURNAMONINE DERIVATIVES FOR THE PROMOTION OF BONE GROWTH |
WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
EP2445512B1 (en) * | 2009-06-23 | 2018-08-29 | The Regents of The University of California | Enhancement of bmp retention |
AU2010310457B2 (en) | 2009-10-23 | 2015-07-02 | Amgen Inc. | Vial adapter and system |
WO2011128424A1 (en) | 2010-04-16 | 2011-10-20 | Novartis Ag | Methods and compositions for improving implant osseointegration |
EP2569010B1 (en) | 2010-05-14 | 2017-04-12 | Amgen, Inc | High concentration antibody formulations |
AU2011265005B2 (en) | 2010-06-07 | 2015-04-09 | Amgen Inc. | Drug delivery device |
WO2013032527A1 (en) | 2011-09-02 | 2013-03-07 | The Regents Of The University Of California | Llp2a-bisphosphonate conjugates for osteoporosis treatment |
JP2014503482A (ja) | 2010-11-05 | 2014-02-13 | ノバルティス アーゲー | Il−17アンタゴニストを用いて関節リウマチを治療する方法 |
CN103649118A (zh) | 2011-03-01 | 2014-03-19 | 安进公司 | 双特异性结合剂 |
SG193610A1 (en) | 2011-03-25 | 2013-11-29 | Amgen Inc | Anti - sclerostin antibody crystals and formulations thereof |
CA2831100C (en) | 2011-03-31 | 2020-02-18 | Mark Dominis Holt | Vial adapter and system |
DK3404041T3 (da) | 2011-04-19 | 2020-08-24 | Amgen Inc | Fremgangsmåde til behandling af osteoporose |
PL2699293T3 (pl) | 2011-04-20 | 2019-08-30 | Amgen Inc. | Urządzenie do wstrzykiwania automatycznego |
US20140056912A1 (en) | 2011-04-29 | 2014-02-27 | Novartis Ag | Methods of treating squamous cell carcinoma |
HUE039786T2 (hu) | 2011-08-04 | 2019-02-28 | Amgen Inc | Csonthiány-defektusok kezelési módszere |
CA3080331C (en) | 2011-10-14 | 2023-06-06 | Amgen Inc. | Injector and method of assembly |
KR20190120401A (ko) | 2011-12-28 | 2019-10-23 | 암젠 인크 | 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법 |
EP2869844B2 (en) | 2012-07-05 | 2023-06-21 | UCB Pharma S.A. | Treatment for bone diseases |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
EP4234694A3 (en) | 2012-11-21 | 2023-09-06 | Amgen Inc. | Drug delivery device |
WO2014118705A1 (en) | 2013-01-31 | 2014-08-07 | Novartis Ag | Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists |
EP2968736A4 (en) | 2013-03-15 | 2016-11-09 | Amgen Inc | ADJUSTABLE TO A BODY SHAPE AUTO INJECTOR DEVICE |
WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
US10092703B2 (en) | 2013-03-15 | 2018-10-09 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
EP3593839A1 (en) | 2013-03-15 | 2020-01-15 | Amgen Inc. | Drug cassette |
MX369360B (es) * | 2013-03-20 | 2019-11-06 | Baylor College Medicine | ANTICUERPOS ANTI-TGFß O FRAGMENTOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE OSTEOGÉNESIS IMPERFECTA (0I). |
ES2853748T3 (es) | 2013-03-22 | 2021-09-17 | Amgen Inc | Inyector y método de montaje |
WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
US11097055B2 (en) | 2013-10-24 | 2021-08-24 | Amgen Inc. | Injector and method of assembly |
MX2016005315A (es) | 2013-10-24 | 2016-08-11 | Amgen Inc | Sistema de administracion de farmacos con control sensible a la temperatura. |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
SG10201811702TA (en) | 2014-05-07 | 2019-01-30 | Amgen Inc | Autoinjector with shock reducing elements |
JP6822843B2 (ja) | 2014-06-03 | 2021-01-27 | アムジエン・インコーポレーテツド | 薬物送達装置によって収集されたデータを遠隔で処理するためのシステム及び方法 |
JP6766040B2 (ja) | 2014-10-14 | 2020-10-07 | アムジエン・インコーポレーテツド | 視覚および可聴インジケータを備える薬剤注射装置 |
MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
WO2016100055A1 (en) | 2014-12-19 | 2016-06-23 | Amgen Inc. | Drug delivery device with live button or user interface field |
JP6716566B2 (ja) | 2014-12-19 | 2020-07-01 | アムジエン・インコーポレーテツド | 近接センサ付き薬物送達装置 |
AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
JP6484345B2 (ja) | 2015-02-17 | 2019-03-20 | アムジエン・インコーポレーテツド | 固定及び/または戻りが真空によって支援された薬物送達装置 |
JP2018512184A (ja) | 2015-02-27 | 2018-05-17 | アムジエン・インコーポレーテツド | 針ガードの移動に対する抵抗力の閾値が調整可能な針ガード機構を備えた薬物送達装置 |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
US11351308B2 (en) | 2015-12-09 | 2022-06-07 | Amgen Inc. | Auto-injector with signaling cap |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
EP3721922B1 (en) | 2016-03-15 | 2022-05-04 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
ES2959783T3 (es) | 2016-05-13 | 2024-02-28 | Amgen Inc | Conjunto de cubierta protectora de vial |
WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
US11541176B2 (en) | 2016-06-03 | 2023-01-03 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
US11285266B2 (en) | 2016-07-01 | 2022-03-29 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
AU2017310412A1 (en) | 2016-08-08 | 2019-02-21 | Amgen Inc. | Method of improving connective tissue attachment using anti-sclerostin antibodies |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
EP3554256B1 (en) | 2016-12-15 | 2023-07-19 | Société des Produits Nestlé S.A. | Compositions and methods that modulate vitamin d and bone mineral content in a companion animal |
US10961305B2 (en) | 2016-12-21 | 2021-03-30 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
PT3478719T (pt) | 2016-12-21 | 2021-03-18 | Mereo Biopharma 3 Ltd | Uso de anticorpos anti-esclerostina no tratamento da osteogénese imperfeita |
CA3049780A1 (en) | 2017-01-17 | 2018-07-26 | Amgen Inc. | Injection devices and related methods of use and assembly |
WO2018152073A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
EP3582825A1 (en) | 2017-02-17 | 2019-12-25 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
CA3050927A1 (en) | 2017-03-06 | 2018-09-13 | Brian Stonecipher | Drug delivery device with activation prevention feature |
US11571511B2 (en) | 2017-03-07 | 2023-02-07 | Amgen Inc. | Insertion mechanism and method of inserting a needle of a drug delivery device |
AU2018230486B2 (en) | 2017-03-09 | 2023-05-11 | Amgen Inc. | Insertion mechanism for drug delivery device |
PT3600491T (pt) | 2017-03-28 | 2023-10-18 | Amgen Inc | Sistema e método de haste de êmbolo e conjunto de seringa |
CA3066399A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Torque driven drug delivery device |
EP3634539A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
US11541183B2 (en) | 2017-06-22 | 2023-01-03 | Amgen Inc. | Device activation impact/shock reduction |
CA3063921A1 (en) | 2017-06-23 | 2018-12-27 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
MA49562A (fr) | 2017-07-14 | 2020-05-20 | Amgen Inc | Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion |
IL271173B2 (en) | 2017-07-21 | 2024-04-01 | Amgen Inc | Gas permeable sealing element for drug container and methods of assembly |
JP7242562B2 (ja) | 2017-07-25 | 2023-03-20 | アムジエン・インコーポレーテツド | 容器アクセスシステムを有する薬物送達デバイス及び関連する組立方法 |
EP4085942A1 (en) | 2017-07-25 | 2022-11-09 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
WO2019032482A2 (en) | 2017-08-09 | 2019-02-14 | Amgen Inc. | HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM |
WO2019036181A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | BODY INJECTOR WITH STERILE ADHESIVE PATCH |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
MA50611A (fr) | 2017-10-04 | 2020-08-12 | Amgen Inc | Adaptateur d'écoulement destiné à un dispositif d'administration de médicament |
US11813426B2 (en) | 2017-10-06 | 2023-11-14 | Amgen Inc. | Drug delivery device including seal member for needle of syringe |
EP3694578A1 (en) | 2017-10-09 | 2020-08-19 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
US11826480B2 (en) | 2017-11-03 | 2023-11-28 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
AU2018358749B2 (en) | 2017-11-06 | 2024-02-29 | Amgen Inc. | Drug delivery device with placement and flow sensing |
EP3707075A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Fill-finish assemblies and related methods |
US11191904B2 (en) | 2017-11-10 | 2021-12-07 | Amgen Inc. | Plungers for drug delivery devices |
MX2020004996A (es) | 2017-11-16 | 2020-08-27 | Amgen Inc | Un mecanismo de pestillo de puerta para un dispositivo de administracion de farmacos. |
AU2018368338B2 (en) | 2017-11-16 | 2024-07-25 | Amgen Inc. | Autoinjector with stall and end point detection |
WO2019191534A1 (en) | 2018-03-30 | 2019-10-03 | Amgen Inc. | C-terminal antibody variants |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
GB201810746D0 (en) | 2018-06-29 | 2018-08-15 | Mereo Biopharma 3 Ltd | Use of sclerostin antagonist |
CA3103682A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
MX2021000748A (es) | 2018-07-24 | 2021-03-26 | Amgen Inc | Dispositivos de suministro para administrar farmacos. |
US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
US20210228797A1 (en) | 2018-07-31 | 2021-07-29 | Amgen Inc. | Fluid path assembly for a drug delivery device |
KR20210043607A (ko) | 2018-08-10 | 2021-04-21 | 암젠 인크 | 항체 제약 제형의 제조 방법 |
MA53724A (fr) | 2018-09-24 | 2021-12-29 | Amgen Inc | Systèmes et procédés de dosage interventionnel |
MA53718A (fr) | 2018-09-28 | 2022-01-05 | Amgen Inc | Ensemble d'activation d'échappement de fil de muscle pour un dispositif d'administration de médicament |
MA53815A (fr) | 2018-10-02 | 2022-01-05 | Amgen Inc | Systèmes d'injection pour administration de médicament avec transmission de force interne |
AU2019355979A1 (en) | 2018-10-05 | 2021-03-18 | Amgen Inc. | Drug delivery device having dose indicator |
JP2022504805A (ja) | 2018-10-15 | 2022-01-13 | アムジエン・インコーポレーテツド | 薬物送達デバイスのプラットフォーム式組み立てプロセス |
US12053617B2 (en) | 2018-10-15 | 2024-08-06 | Amgen Inc. | Drug delivery device having damping mechanism |
WO2020091956A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
MA54057A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament |
MX2021012557A (es) | 2019-04-24 | 2021-11-12 | Amgen Inc | Conjuntos y metodos de verificacion de esterilizacion de jeringuillas. |
WO2021030179A1 (en) | 2019-08-12 | 2021-02-18 | Amgen Inc. | Anti-sclerostin antibody formulations |
WO2021041067A2 (en) | 2019-08-23 | 2021-03-04 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
WO2022120080A1 (en) * | 2020-12-03 | 2022-06-09 | University Of Massachusetts | Development of novel gene therapeutics for fibrodysplasia ossificans progressiva |
CN113354724A (zh) * | 2021-04-28 | 2021-09-07 | 蒋青 | 骨硬化蛋白及其在制备治疗或预防阿尔兹海默症的相关产品上应用 |
AU2022279223A1 (en) | 2021-05-21 | 2023-10-19 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
Family Cites Families (176)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US649445A (en) * | 1899-08-31 | 1900-05-15 | James Alpheus Green | Steam-injector for fire-boxes of steam-boilers. |
US4018884A (en) | 1975-06-26 | 1977-04-19 | Hoffmann-La Roche Inc. | Fluorogenic materials and labeling techniques |
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4378110A (en) * | 1978-04-17 | 1983-03-29 | Greene Ronald W | Continuous paper sorting machine |
US4528266A (en) | 1979-10-01 | 1985-07-09 | George Pieczenik | Method of inserting unique DNA sequences into DNA vectors |
US4359535A (en) | 1979-10-01 | 1982-11-16 | George Pieczenik | Autonomously replicating DNA containing inserted DNA sequences |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4427115A (en) | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
DE3417525C1 (de) | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen |
US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
US5087571A (en) | 1984-06-22 | 1992-02-11 | President And Fellows Of Harvard College | Method for providing a cell culture from a transgenic non-human mammal |
US4801542A (en) | 1984-10-12 | 1989-01-31 | Zymogenetics, Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
SG64329A1 (en) | 1984-11-16 | 1999-04-27 | American Cyanamid Co | Antitumor antibiotics (LL-E33288 complex) |
US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
US4897255A (en) | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
CA1293460C (en) | 1985-10-07 | 1991-12-24 | Brian Lee Sauer | Site-specific recombination of dna in yeast |
US4744981A (en) | 1985-10-17 | 1988-05-17 | Neorx Corporation | Trichothecene antibody conjugates |
US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
ATE132266T1 (de) | 1987-05-01 | 1996-01-15 | Stratagene Inc | Mutagenesetest durch verwendung von nicht menschlichen lebewesen, die test-dns-sequenzen enthalten |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
ATE112172T1 (de) | 1987-10-30 | 1994-10-15 | American Cyanamid Co | Targetformer von antitumor-methyltrithioagenzien. |
US5254678A (en) | 1987-12-15 | 1993-10-19 | Gene Shears Pty. Limited | Ribozymes |
EP0329184A3 (en) | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimers and antimeric conjugation |
US4988496A (en) | 1988-05-31 | 1991-01-29 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
US5221778A (en) | 1988-08-24 | 1993-06-22 | Yale University | Multiplex gene regulation |
DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
CA1340323C (en) | 1988-09-20 | 1999-01-19 | Arnold E. Hampel | Rna catalyst for cleaving specific rna sequences |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
JP2752788B2 (ja) | 1989-01-23 | 1998-05-18 | カイロン コーポレイション | 感染および過剰増殖障害の為の組換え療法 |
GB8903022D0 (en) | 1989-02-10 | 1989-03-30 | Celltech Ltd | Chemical compounds |
US5175383A (en) | 1989-02-17 | 1992-12-29 | President And Fellows Of Harvard College | Animal model for benign prostatic disease |
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
GB8914543D0 (en) | 1989-06-23 | 1989-08-09 | Parker David | Chemical compounds |
EP0845537A1 (en) | 1989-08-18 | 1998-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5359051A (en) | 1990-01-11 | 1994-10-25 | Isis Pharmaceuticals | Compounds useful in the synthesis of nucleic acids capable of cleaning RNA |
DE69030172T2 (de) | 1990-01-26 | 1997-06-19 | Immunomedics Inc | Impfstoffe gegen Krebs und Infektionskrankheiten |
US5177197A (en) * | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
US5387742A (en) | 1990-06-15 | 1995-02-07 | Scios Nova Inc. | Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
JPH04141095A (ja) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗hiv改変抗体および改変抗体の調製方法 |
US5070108A (en) | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
EP0554376A4 (en) | 1990-10-22 | 1994-08-24 | Fox Chase Cancer Center | Dna construct for providing rna therapy |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
EP0575485A1 (en) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Process for the development of binding mini-proteins |
US6949505B1 (en) * | 1991-03-11 | 2005-09-27 | Curis, Inc. | Morphogen-induced dendritic growth |
DE69229482T2 (de) | 1991-04-25 | 1999-11-18 | Chugai Seiyaku K.K., Tokio/Tokyo | Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
US5203975A (en) | 1991-10-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Process for cathodic electrodeposition of a clear coating over a conductive paint layer |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION. |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
IL108719A0 (en) | 1993-02-25 | 1994-08-26 | Ortho Pharma Corp | Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them |
FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
US5864027A (en) | 1993-06-07 | 1999-01-26 | Genentech, Inc. | HIV envelope polypeptides |
CA2167391A1 (en) | 1993-07-16 | 1995-01-26 | Robert W. Armstrong | Synthesis of combinatorial arrays of organic compounds through the use of multiple component combinatorial array syntheses |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5453492A (en) * | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
EP0712493A4 (en) | 1993-08-03 | 1997-01-15 | Sphinx Pharma Corp | METHOD FOR THE PREPARATION AND SELECTION OF NON-PEPTIDE COMPOUNDS FOR PHARMACOLOGICAL USE FROM A UNIVERSAL LIBRARY OF ELEMENTS WITH VARIOUS STRUCTURES |
US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
PT733103E (pt) | 1993-11-09 | 2004-07-30 | Targeted Genetics Corp | Criacao de elevados titulos de vectores de aav recombinantes |
AU1068295A (en) | 1993-12-09 | 1995-06-27 | Novartis Ag | Process for the production of combinatorial compound libraries |
DE69430006T2 (de) | 1993-12-15 | 2002-11-28 | Smithkline Beecham Corp., Philadelphia | Verbindungen und verfahren |
WO1995016918A1 (en) | 1993-12-15 | 1995-06-22 | Combichem, Inc. | Combinatorial libraries and methods for their use |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5756810A (en) | 1994-03-11 | 1998-05-26 | Pharmacopeia, Inc. | Process of preparing 3-nitro benzoate compounds in lower alkanol |
DE69535641D1 (de) | 1994-04-29 | 2007-12-27 | Curis Inc | Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen |
JPH10500112A (ja) | 1994-05-06 | 1998-01-06 | ファーマコピーア,インコーポレイテッド | 組合せ ジヒドロベンゾピラン ライブラリー |
US5549974A (en) | 1994-06-23 | 1996-08-27 | Affymax Technologies Nv | Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof |
DE4427221A1 (de) | 1994-08-01 | 1996-02-08 | Gsf Forschungszentrum Umwelt | Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie |
US5463564A (en) | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
US6057421A (en) | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
EP0871705A4 (en) | 1995-06-05 | 2000-01-26 | Human Genome Sciences Inc | CCN TYPE HUMAN GROWTH FACTOR |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
DE69738868D1 (de) | 1996-05-22 | 2008-09-11 | Viventia Biotech Inc | Odieren, und deren verwendung zur vorbeugung und zum nachweis von krebs |
US5989912A (en) | 1996-11-21 | 1999-11-23 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
AU6959898A (en) | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
US6610510B1 (en) * | 1997-04-29 | 2003-08-26 | Regeneron Pharmaceuticals, Inc. | Morphogenic proteins |
CA2293632C (en) | 1997-06-12 | 2011-11-29 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
JP2001512016A (ja) * | 1997-08-01 | 2001-08-21 | ジェンセット | 筋肉およびその他中胚葉組織中で発現される分泌タンパク質の5’est |
US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
US6544485B1 (en) | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
ATE338120T2 (de) * | 1998-11-27 | 2006-09-15 | Ucb Sa | Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung |
WO2000044777A1 (en) | 1999-01-29 | 2000-08-03 | Imclone Systems Incorporated | Antibodies specific to kdr and uses thereof |
ES2332916T3 (es) | 1999-06-09 | 2010-02-15 | Genentech Inc | Composiciones y metodo para el tratamiento de tumores. |
JP4141095B2 (ja) | 1999-10-29 | 2008-08-27 | 三洋電機株式会社 | 半導体装置とその製造方法 |
AU4196801A (en) | 2000-03-02 | 2001-09-12 | Amgen Inc | Chordin-like-2 molecules and uses thereof |
EP1290169A2 (en) | 2000-06-01 | 2003-03-12 | Amgen, Inc. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
EP1366156A2 (en) | 2000-06-19 | 2003-12-03 | F. Hoffmann-La Roche Ag | Osteolevin gene polymorphisms |
CA2632702A1 (en) | 2000-09-01 | 2002-03-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
SI1324776T2 (en) | 2000-10-12 | 2018-06-29 | Genentech, Inc. | Concentrated protein formulations with reduced viscosity |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
CA2374027A1 (en) * | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
DE10145772A1 (de) | 2001-09-17 | 2003-04-10 | Bayer Cropscience Ag | DELTA·1·-Pyrroline |
JP4467304B2 (ja) | 2001-12-06 | 2010-05-26 | バイオコントロール システムズ,インコーポレイティド | サンプル収集および試験システム |
US20030186915A1 (en) | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
EP2277522B1 (en) | 2002-03-01 | 2012-11-21 | UCB Manufacturing, Inc. | Methods for increasing or decreasing bone density and identifying molecules |
US7799523B2 (en) | 2002-04-03 | 2010-09-21 | Celltech R & D, Inc. | Association of polymorphisms in the SOST gene region with bone mineral density |
FR2838379B1 (fr) | 2002-04-12 | 2005-06-24 | Valeo Climatisation | Dispositif de purification de l'air de l'habitacle d'un vehicule automobile |
WO2003106657A2 (en) | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
US7893218B2 (en) * | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
CA2504493C (en) | 2002-11-01 | 2015-12-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides |
DE10255152A1 (de) | 2002-11-26 | 2004-06-03 | Von Langen Ursula Lang | Schadstoffsauger |
US7642238B2 (en) | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
US20040141875A1 (en) | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
ES2379689T3 (es) | 2003-03-14 | 2012-04-30 | Ucb Manufacturing, Inc. A Company Incorporated Under The Laws Of The State Of Delaware | Complejo de esclerostina y nogina o cordina, y agentes que modulan la formación de dicho complejo |
US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
US7381409B2 (en) | 2003-06-16 | 2008-06-03 | Celltech R&D, Inc. | Antibodies specific for sclerostin and methods of screening and use therefor |
US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
US20050267233A1 (en) | 2004-05-25 | 2005-12-01 | Joshi Ashok V | Anti-microbial handle system |
CA2574881C (en) | 2004-08-04 | 2013-01-08 | Amgen Inc. | Antibodies to dkk-1 |
US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
WO2007080129A1 (en) | 2006-01-13 | 2007-07-19 | A Chan Holding B.V. | Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction |
WO2008061013A2 (en) | 2006-11-10 | 2008-05-22 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
EP2094731A2 (en) | 2006-11-10 | 2009-09-02 | UCB Pharma S.A. | Anti human sclerostin antibodies |
ES2666650T3 (es) | 2006-12-29 | 2018-05-07 | OstéoQC Inc. | Métodos para alterar el crecimiento óseo mediante la administración de antagonista o agonista de sost o wise |
BRPI0807205A2 (pt) | 2007-02-02 | 2014-07-22 | Novartis Ag | Moduladores de ligantes esclerostina para tratamento de distúrbios relacionados ao osso |
EP2131860B1 (en) | 2007-03-20 | 2013-12-18 | Eli Lilly & Company | Anti-sclerostin antibodies |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素(sclerostin)抗體組合物及使用方法 |
AU2008320823B2 (en) | 2007-11-02 | 2013-01-17 | Novartis Ag | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6) |
EP2628486A3 (en) | 2007-12-14 | 2013-10-30 | Amgen, Inc. | Method for treating bone fracture with anti-sclerostin antibodies |
MX2010013239A (es) | 2008-06-03 | 2011-02-24 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
WO2010100179A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Self-forming gel system for sustained drug delivery |
WO2010100200A2 (en) | 2009-03-05 | 2010-09-10 | Novartis Ag | Lyophilised antibody formulation |
WO2010115932A1 (en) | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
WO2010130830A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
MX354481B (es) | 2010-10-27 | 2018-03-07 | Amgen Inc | Anticuerpos dkk1 y métodos de uso. |
-
1999
- 1999-11-24 AT AT99963986T patent/ATE338120T2/de active
- 1999-11-24 CA CA2352532A patent/CA2352532C/en not_active Expired - Lifetime
- 1999-11-24 DK DK06011535.9T patent/DK1721979T3/da active
- 1999-11-24 IL IL14326699A patent/IL143266A0/xx active IP Right Grant
- 1999-11-24 NZ NZ512122A patent/NZ512122A/en not_active IP Right Cessation
- 1999-11-24 JP JP2000585404A patent/JP4813660B2/ja not_active Expired - Lifetime
- 1999-11-24 ES ES10008049.8T patent/ES2639020T3/es not_active Expired - Lifetime
- 1999-11-24 DK DK10008049.8T patent/DK2261335T3/en active
- 1999-11-24 MX MX2013001685A patent/MX343200B/es unknown
- 1999-11-24 EP EP10008049.8A patent/EP2261335B1/en not_active Expired - Lifetime
- 1999-11-24 ES ES06011535T patent/ES2350454T3/es not_active Expired - Lifetime
- 1999-11-24 DK DK99963986.7T patent/DK1133558T4/en active
- 1999-11-24 CN CN2008100992340A patent/CN101469329B/zh not_active Expired - Lifetime
- 1999-11-24 DE DE69933044.0T patent/DE69933044T3/de not_active Expired - Lifetime
- 1999-11-24 MX MXPA01005275A patent/MXPA01005275A/es active IP Right Grant
- 1999-11-24 PT PT99963986T patent/PT1133558E/pt unknown
- 1999-11-24 NZ NZ552959A patent/NZ552959A/en not_active IP Right Cessation
- 1999-11-24 DE DE69942782T patent/DE69942782D1/de not_active Expired - Lifetime
- 1999-11-24 PT PT06011535T patent/PT1721979E/pt unknown
- 1999-11-24 CN CN99815505.5A patent/CN1333828B/zh not_active Expired - Lifetime
- 1999-11-24 ES ES99963986.7T patent/ES2272093T5/es not_active Expired - Lifetime
- 1999-11-24 WO PCT/US1999/027990 patent/WO2000032773A1/en active Application Filing
- 1999-11-24 EP EP99963986.7A patent/EP1133558B2/en not_active Expired - Lifetime
- 1999-11-24 US US09/449,218 patent/US6395511B1/en not_active Expired - Lifetime
- 1999-11-24 PT PT100080498T patent/PT2261335T/pt unknown
- 1999-11-24 NZ NZ568033A patent/NZ568033A/en not_active IP Right Cessation
- 1999-11-24 BR BRPI9915679A patent/BRPI9915679B8/pt not_active IP Right Cessation
- 1999-11-24 AT AT06011535T patent/ATE481487T1/de active
- 1999-11-24 EP EP06011535A patent/EP1721979B1/en not_active Revoked
-
2000
- 2000-09-21 US US09/668,037 patent/US6495736B1/en not_active Expired - Lifetime
- 2000-09-21 US US09/668,529 patent/US6489445B1/en not_active Expired - Lifetime
- 2000-09-21 US US09/668,021 patent/US6803453B1/en not_active Expired - Lifetime
-
2001
- 2001-05-21 IL IL143266A patent/IL143266A/en not_active IP Right Cessation
- 2001-05-23 ZA ZA200104234A patent/ZA200104234B/en unknown
-
2002
- 2002-03-07 US US10/095,248 patent/US7572899B2/en not_active Expired - Fee Related
- 2002-07-26 HK HK02105515.3A patent/HK1044171B/zh not_active IP Right Cessation
-
2003
- 2003-03-06 US US10/384,893 patent/US7192583B2/en not_active Expired - Lifetime
-
2004
- 2004-02-27 US US10/788,606 patent/US7758858B2/en not_active Expired - Fee Related
-
2006
- 2006-11-09 CY CY20061101623T patent/CY1106260T1/el unknown
-
2007
- 2007-10-31 US US11/931,812 patent/US7977312B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/931,853 patent/US20110150866A1/en not_active Abandoned
- 2007-10-31 US US11/931,768 patent/US7994299B2/en not_active Expired - Fee Related
-
2009
- 2009-12-31 HK HK09112388.6A patent/HK1135726A1/xx not_active IP Right Cessation
-
2010
- 2010-12-10 CY CY20101101148T patent/CY1110982T1/el unknown
- 2010-12-30 IL IL210392A patent/IL210392A/en not_active IP Right Cessation
-
2011
- 2011-06-30 JP JP2011145326A patent/JP5691036B2/ja not_active Expired - Lifetime
-
2012
- 2012-10-04 US US13/644,728 patent/US8986685B2/en not_active Expired - Fee Related
-
2015
- 2015-02-19 US US14/626,274 patent/US9791462B2/en not_active Expired - Fee Related
-
2017
- 2017-08-30 CY CY20171100914T patent/CY1119263T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110982T1 (el) | Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων | |
ES2154624T1 (es) | Regulacion de la expresion de la quinolato fosforribosil transferasa. | |
CO5590973A2 (es) | Acido nucleico de adenovirus de simio y secuiencias de aminoacidos, vectores que contienen los mismos y metodos de uso | |
ATE310090T1 (de) | Gereinigte coprinus laccasen und nukleinsäuren welche dafür kodieren | |
EE04378B1 (xx) | LAG-3 pleissimisteisendid | |
EP1001025A3 (en) | Outer membrane proteins from actinobacillus pleuropneumoniae | |
HUP9904414A2 (hu) | A neuritin neurogén | |
FI961202A0 (fi) | Grb3-3-geeni, sen variantteja ja niiden käyttöjä | |
MXPA01008605A (es) | Proteina de enlace del antigeno goodpasture. | |
FI972170A0 (fi) | Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, näitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö | |
DE69739346D1 (de) | Gereinigtes sr-p70 protein | |
SE9602822D0 (sv) | New receptor | |
DK0643719T3 (da) | Nukleinsyresekvenser, som koder for eller er komplementære til nukleinsyresekvenser, som koder for interleukin 9-receptor | |
DE69526087D1 (de) | Or-1, ein wais-rezeptor der nuklearen rezeptoren familie | |
AR022150A1 (es) | Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados | |
WO1996029407A3 (en) | Cellubrevin homologs | |
MXPA01004291A (es) | Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos. | |
SE9801098D0 (sv) | Receptors | |
ATE344802T1 (de) | Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure | |
WO2002083727A3 (de) | Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse | |
WO2002046378A3 (en) | Alternative pol k nucleotide and amino acid sequence and methods for using | |
EE200100234A (et) | PRV-1-geen ja selle kasutamine | |
DK1056872T3 (da) | DNA-sekvenser indeholdende en overförselsmekanisme ved konjugering | |
ATE286535T1 (de) | Regulatorisches protein pke 83 aus humanen keratinozyten | |
MX9708943A (es) | Genes de polifenol oxidasa de la lengua y platano. |